What does the company do?
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of pharmaceutical and nutritional products. The Company had two segments: Pharmaceuticals and Nutritionals. The Pharmaceuticals segment is made up of the global pharmaceutical and international consumer medicines business. The Nutritionals segment consists of Mead Johnson Nutritionals (Mead Johnson), primarily an infant formula and children’s nutritionals business. In June 2008, BMS acquired Kosan Biosciences, Inc., a developer of oncology products. In August 2008, the Company completed the divestiture of its ConvaTec business to Cidron Healthcare Limited, an affiliate of Nordic Capital Fund VII and Avista. In December 2008, BMS completed the sale of its brand business in Egypt to GlaxoSmithKline. In July 2009, the Company's branded generics business, which comprises a portfolio of 13 branded pharmaceuticals was acquired by GlaxoSmithKline plc.
How much does the company sell and earn?
Investors need to know how much stuff or services a company sells, and how much of that total it keeps as income (or profit) to grow its business or return to shareholders. The more of each, the better. In general, look for companies that sell and earn more than peers.
- Bristol Myers one-year sales: 21.14 Bil.
Difference from the average for the Drug Manufacturers - Major group: -49.46% - Bristol Myers one-year income: 3.77 Bil.
Difference from the average for the Drug Manufacturers - Major group: -49.37%| Sales & Income (past 12 months) | Company | Industry |
|---|
| Sales | 21.14 Bil | 41.82 Bil | | Income | 3.77 Bil | 7.45 Bil |
How fast is the company growing?
- Bristol Myers one-year sales growth: 3.50%.
Difference from the average for the Drug Manufacturers - Major group: 2.10 pct. pts. - Bristol Myers one-year income growth: 32.10%.
Difference from the average for the Drug Manufacturers - Major group: 26.80 pct. pts.| Sales & Income Growth (past 12 months) | Company | Industry |
|---|
| Sales Growth | 3.50% | 1.40% | | Income Growth | 32.10% | 5.30% |
How profitable is the company?
Investors prefer companies that increase profit margins -- the percentage of sales that they keep -- every year. This is accomplished either by lowering expenses or raising prices. Look for companies that consistently find ways to squeeze more profits out of sales than their peers.
- Bristol Myers one-year net profit margin: 23.5%
Difference from the company's 5-year average net profit margin: 7.8 pct. pts.
Difference from the average for the Drug Manufacturers - Major group: 4.9 pct. pts.
| Net profit margins (%) |
|---|
| Company | 23.5% | | Company 5-Yr Avg. | 15.7% | | Industry | 18.6% |
How is the company's financial health?
The debt/equity ratio shows how much a firm has borrowed as a percentage of its stock equity. The lower, the better.
- Bristol Myers debt/equity ratio: 0.45.
Difference from the average for the Drug Manufacturers - Major group: -80.26%.
| | Company | Industry |
|---|
| Debt/equity ratio | 0.45 | 2.28 |
|
Recent News